Form 4 for LXRX LEXICON PHARMACEUTICALS, INC.
Accepted 2023-11-17 00:00:00 ET · period of report 2023-11-16 · accession 0001127602-23-027850 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-17 | 2023-11-16 | LXRX | COATS LONNEL | CEO, Dir | P - Purchase | $1.05 | +90.0K | 914.4K | +11% | +$94.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-16 | P | A | 90,000 | $1.05 | 914,359 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $1.05 to $1.06 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Coats hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected. |